|
|
“This was a great meeting, specifically to see
how major contributors to
clinical trials interact & develop the same requirements for the future Biomarker world.”
Business & Research
Development, Mount Sinai Hospital
|
| Keynote
Presentations: |
 |
Overview of Biomarkers:
What Needs to be Done to Identify New Ones and Validate Them
Samir Hanash, M.D., Ph.D., Director,
Molecular Diagnostics Program,
Fred Hutchinson Cancer Research Center |
|
|
 |
Proteomic Technologies for Cancer Research:
A Strategic Plan for Translating Discoveries to the Clinic
Henry Rodriguez, Ph.D.,MBA, Director, Clinical Proteomic Technologies for Cancer,
Office of Technology and Industrial Relations, Office of the Director, National Cancer Institute |
|
|
|
|
J. Carl Barrett, Ph.D.,
Global Head, Biomarker Development Oncology, Novartis Institutes for
BioMedical Research |
SCIENTIFIC ADVISORY BOARD
Kenneth Evans, Ph.D., President and Chief Executive Officer, Ontario Cancer Biomarker Network
Anna Astriab Fisher, Ph.D., Vice President, Assay Development, GenTel BioSciences, Inc.
Robert Phillips, Ph.D., Chief Operating Officer, Ontario Institute for Cancer Research
David S. Lester, Ph.D., New York Site Head, Pfizer Human Health Technologies, Global Clinical Technology, PGRD
NEW THIS YEAR
- CASE STUDIES:
Biomarker Validation to Clinical Implementation
SUNDAY, OCTOBER 14 - 5:00-6:00pm Early Registration
|
|
|
